Differential molecular changes in patients with asymptomatic long-segment Barrett's esophagus treated by antireflux surgery or medical therapy

American Journal of Surgery

Volumn 199, Issue 2, 2010, Pages 137-143

  Babar, Mawash ^a   Ennis, Darren ^a   Abdel Latif, Mohamed ^a   Byrne, Patrick J ^a   Ravi, Narayanasamy ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Barrett's esophagus; Gastroesophageal reflux disease; Nuclear factor B; Oxidative stress

Indexed keywords

CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENDOSCOPIC BIOPSY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STOMACH FUNDOPLICATION;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CYTOKINES; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; NF-KAPPA B; OXIDATIVE STRESS; PROTON PUMP INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 74649084296     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.11.032     Document Type: Article

References (46)

1. Cameron A.J. Barrett's esophagus: does the incidence of adenocarcinoma matter?. Am J Gastroenterol 92 (1997) 193-194
2. Pera M., Cameron A.J., Trastek V.F., et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 (1993) 510-513
3. Provenzale D., Kemp J.A., Arora S., et al. A guide for surveillance of patients with Barrett's oesophagua. Am J Gastroenterol 89 (1994) 670-801
4. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 (2004) 405-406
5. Maeda S., and Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 99 (2008) 836-842
6. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
7. O'Riordan J.M., Abdel-Latif M.M., Ravi N., et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100 (2005) 1257-1264
8. Duggan S.P., Gallagher W.M., Fox E.J., et al. Low pH induces co-ordinate regulation of gene expression in oesophageal cells. Carcinogenesis 27 (2006) 319-327
9. Murphy J.O., Ravi N., Byrne P.J., et al. Neither antioxidants nor COX-2 inhibition against esophageal inflammation protect against esophageal inflammation in an experimental model of severe reflux. J Surg Res 142 (2008) 20-27
10. Abdel-Latif M.M., O'Riordan J.M., Ravi N., et al. Activated nuclear factor kappa-B and cytokine profiles in the esophagus parallel tumor regression following neo-adjuvant chemoradiotherapy. Dis Esophagus 18 (2005) 246-252
11. O'Riordan J.M., Byrne P.J., Ravi N., et al. Long-term clinical and pathologic response of Barrett's esophagus after anti-reflux surgery. Am J Surg 188 (2004) 27-33
12. Hofstetter W.L., Peters J.H., De Meester T.R., et al. Long-term outcomes of anti-reflux surgery in patients with Barrett's esophagus. Ann Surg 234 (2001) 532-538
13. Rantanen T.K., Rasanen J.V., Sihvo E.I.T., et al. The impact of anti-reflux surgery on oxidative stress of esophageal mucosa caused by gastroesophageal reflux disease: 4-yr follow-up study. Am J Gastroenterol 101 (2006) 222-228
14. Wetscher G.J., Hinder R.A., Bagchi D., et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg 170 (1995) 552-557
15. Johnson L.F., and DeMeester T.R. Twenty-four hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 62 (1974) 325-332
16. Rossetti M.E., Libermann-Heffert D., and Brauner R.B. The "Rossetti" modification of the Nissen fundoplication: technique and results. Dis Esophagus 9 (1996) 258-262
17. Comstock G.W., Norkus E.P., Hoffman S.C., et al. Stability of ascorbic acid, carotenoids, retinol, and tocopherols in plasma stored at -70 degrees C for 4 years. Cancer Epidemiol Biomarkers Prev 4 (1995) 505-507
18. Kallner A., Hartmann D., and Hornig D. Steady-state turnover and body pool of ascorbic acid in man. Am J Clin Nutr 32 (1979) 530-539
19. Levine M., Conry-Cantilena C., Wang Y., et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 93 (1996) 3704-3709
20. Madrigal L., Lynch S., Feighery C., et al. Flow cytometric analysis of surface major histocompatibility complex class II expression on human epithelial cells prepared from small intestinal biopsies. J Immunol Methods 158 (1993) 207-214
21. Basu K.K., Bale R., West K.P., et al. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 14 (2002) 1187-1192
22. Theisen J., Peters J.H., Fein M., et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg 241 (2005) 63-68
23. Chang E.Y., Morris C.D., Seltman A.K., et al. The effect of anti-reflux surgery on esophageal carcinogenesis in patients with Barrett's esophagus: a systematic review. Ann Surg 246 (2007) 11-21
24. Pikarsky E., Porat R.M., Stein I., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
25. Abdel-Latif M.M., O'Riordan J., Windle H.J., et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239 (2004) 491-500
26. Oh D.S., DeMeester S.R., Vallbohmer D., et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg 142 (2007) 554-560
27. Lin S.C., Liu C.J., Yeh W.I., et al. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 243 (2006) 45-47
28. Kim L.H., Shin H.D., Park B.L., et al. Identification of variants in NFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients. Hum Mutat 21 (2003) 652-653
29. Karban A.S., Okazaki T., Panhuysen C.I., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13 (2004) 35-45
30. Curran J.E., Weinstein S.R., and Griffiths L.R. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 188 (2002) 103-107
31. Huajie B.U., Inger R., Xiao-Feng S., et al. Importance of polymorphisms in NF-κB1 and NF-κBIα genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 133 (2007) 859-866
32. Jaiswal K., Lopez-Guzman C., Souza R.F., et al. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 290 (2006) G335-G342
33. Mariette C., Piessen G., Leteurtre E., et al. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. Surgery 143 (2008) 58-71
34. Burnat G., Rau T., Elshimi E., et al. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol 42 (2007) 1460-1465
35. Kaur B.S., and Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 283 (2002) G327-G334
36. Song S., Guha S., Liu K., et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 56 (2007) 1512-1521
37. Sarela A.I., Hick D.G., Verbeke C.S., et al. Persistent acid and bile reflux in asymptomatic patients with Barrett's esophagus receiving proton pump inhibitor therapy. Arch Surg 139 (2004) 547-551
38. Zhang F., Altorki N.K., Wu Y.C., et al. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 121 (2001) 1391-1399
39. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285 (2001) 2331-2338
40. Wetscher G.J., Gadenstaetter M., Klingler P.J., et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. Ann Surg 234 (2001) 627-632
41. Lundell L., Miettinen P., Myrvold H.E., et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 192 (2001) 172-181
42. Lundell L., Miettinen P., Myrvold H.E., et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 12 (2000) 879-887
43. Isolauri J., Luostarinen M., Viljakka M., et al. Long-term comparison of antireflux surgery versus conservative therapy for reflux esophagitis. Ann Surg 225 (1997) 295-299
44. Parrilla P., Martinez de Haro L.F., Ortiz A., et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 237 (2003) 291-298
45. Rantanen T.K., Sihvo E.I., Rasanen J.V., et al. Gastroesophageal reflux disease as a cause of death is increasing: analysis of fatal cases after medical and surgical treatment. Am J Gastroenterol 102 (2007) 246-253
46. DeMeester T.R. Surgical therapy for Barrett's esophagus: prevention, protection and excision. Dis Esophagus 15 (2002) 109-116